CN1833665A - Mangosteen peel extracts, its extraction method and medicine use - Google Patents
Mangosteen peel extracts, its extraction method and medicine use Download PDFInfo
- Publication number
- CN1833665A CN1833665A CN 200610016501 CN200610016501A CN1833665A CN 1833665 A CN1833665 A CN 1833665A CN 200610016501 CN200610016501 CN 200610016501 CN 200610016501 A CN200610016501 A CN 200610016501A CN 1833665 A CN1833665 A CN 1833665A
- Authority
- CN
- China
- Prior art keywords
- peel
- extract
- carcinia mangostana
- mangostana
- carcinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims description 27
- 240000006053 Garcinia mangostana Species 0.000 title abstract description 11
- 235000017048 Garcinia mangostana Nutrition 0.000 title abstract description 11
- 238000000605 extraction Methods 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 11
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 4
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 description 13
- 210000004165 myocardium Anatomy 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 241000218628 Ginkgo Species 0.000 description 8
- 235000011201 Ginkgo Nutrition 0.000 description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000007766 cera flava Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- -1 flavone compounds Chemical class 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000546193 Clusiaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 240000000716 Durio zibethinus Species 0.000 description 1
- 235000006025 Durio zibethinus Nutrition 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001776 parthenogenetic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An extract of mangosteen fruit peel as a new Chinese-medicinal material is prepared from the peel of mangosteen fruit through breaking, extracting in alcohol and recovering alcohol. It can be used to treat hyperlipemia, coronary heart disease, angina pectoris and myocardial ischemia.
Description
Technical field
The present invention relates to extract and extracting method and medicinal usage thereof in a kind of new Chinese medicine material.
Background technology
Garcinia mangostana (mangosteen Carcinia mangostana L.), the original name mangosteen.Originate in Malaysian archipelago, modern Guangxi, Hainan abound with.Belong to the evergreen medium-sized arbor of Guttiferae, height of tree 10-20 rice, the tree type is attractive in appearance.Single leaf is to life, oval, keratin, Hua Dingsheng, the petal redness, the 2-4 month blooms, aubergine during fruit maturation, in seed 1-2 grain is arranged, brown, sarcocarp white is transparent, the fresh and sweet soft cunning of distinguishing the flavor of.Effect: the Cortex Garciniae growth is slow, plants just result of back 8-10, and the fructescence 6-7 month, sarcocarp contains soluble solid 16.8%, citric acid 0.63%, also contains other vitamin B1, B2, C4 and mineral, is typical tropical fruit (tree).
Garcinia mangostana is the aiphyllium with dense tree crown, height of tree 10-25 rice.The fruit parthenogenetic reproduction, the diameter 6-7 centimetre epidermis of fruit is solid smooth, be green during the color of the leather immaturity, transfers black purple or pink when ripe to, in the edible sarcocarp of 4-8 lobe is arranged, local flavor delicate fragrance is sweet and a bit sour.1-2 grain seed is arranged in each fruit.
The general plantation of Garcinia mangostana just began the result in 10 years, and is very strict to environmental requirement, therefore is genuine green fruit, and very famous and precious, its delicate fragrance gas is refreshing, and lubricious and oiliness stagnating is equally celebrated for their achievements with Durio Zibethinus murr, is known as " queen in the fruit ".Effect: purify the blood, cholesterol reducing.
Garcinia mangostana sarcocarp accounts for about the 20-30% of gross weight, and remainder is a peel, throws away as garbage.Show through preliminary chemistry and pharmacodynamic study: contain a large amount of flavone compounds in the peel of Carcinia mangostana L., have stronger biological activity aspect the reduction hyperlipidemia.Resourceful peel of Carcinia mangostana L. exploitation is become atorvastatin, and the hyperlipemic patients crowd at vast is with a wide range of applications.
At present, relevant peel of Carcinia mangostana L. total extract and extracting method thereof and medicinal usage thereof are not seen report.
Summary of the invention
One of purpose of the present invention provides a kind of peel of Carcinia mangostana L. extract.
Two of purpose of the present invention provides a kind of peel of Carcinia mangostana L. that utilizes and extracts the method for preparing peel of Carcinia mangostana L. extract.
Three of purpose of the present invention has provided the medicinal usage of peel of Carcinia mangostana L. extract.
For achieving the above object, the present invention takes peel of Carcinia mangostana L. extract extraction process for purification to be:
A. peel of Carcinia mangostana L. is pulverized, under 30-80 ℃ of condition, doubly measured the 30%-95% ethanol extraction 3 times, be respectively 3h, 2h, 1h at every turn, filter merge extractive liquid, with 20-25;
B. on the extracting solution that step a is obtained, reclaim ethanol to extractum, drying.
Because of Cortex Garciniae is grown slow, 8-10 ability result after kind, the fructescence 6-7 month, sarcocarp contains soluble solid only 16.8%, and peel accounts for more than the 70%-80% of fruit, and resource is very abundant, through studies show that it is rich in effective ingredient such as total flavones, be very precious new medical material, do not see report, its blood lipid-lowering medicine purposes belongs to first to be found.Peel of Carcinia mangostana L. extract is characterized by light yellow to brown, and is Powdered, bitter in the mouth, water soluble, ethanol etc.This peel of Carcinia mangostana L. extract content of total flavone accounts for more than 2% of peel of Carcinia mangostana L. dry weight.
When the present invention be used for preparation treatment hyperlipidemia, when resisting myocardial ischemia, treating coronary heart disease, anginal medicine, its oral or parenteral, all be safe, under oral situation, it can any conventionally form administration, as powder, granule, tablet, capsule, pill, solution, suspension, syrup, buccal tablets, sublingual lozenge etc.: when this medicine parenteral, can take any conventionally form, for example injection: as intravenous injection, ointment, suppository, percutaneous dosing, inhalant etc.
The present invention prepares the treatment hyperlipidemia, resist myocardial ischemia, treat coronary heart disease, anginal medicine is to be made of effective ingredient monomer or the effective ingredient excipient with solid or liquid, the excipient of solid used herein or liquid is well known in the art, lift several object lessons below, powder is the powder agent that takes orally, its excipient has lactose, starch, paste essence, calcium carbonate, synthetic or puritan filler aluminum, magnesium oxide, magnesium stearate, sodium bicarbonate, dry yeast etc.; The excipient of solution has water, glycerol, propylene glycol, simple syrup, ethanol, ethylene glycol, Polyethylene Glycol, Sorbitol etc.; The excipient of ointment can use fatty oil, agnolin, vaseline, glycerol, Cera Flava, wood are cured, white oil, resin, the senior cured fatty oil of use, agnolin, vaseline, glycerol, Cera Flava, wooden cured, white oil, resin, senior water-repelling agent or the hydrophilizing agent that is combined into such as cured.
The invention has the beneficial effects as follows that peel of Carcinia mangostana L. extract belongs to the new medicinal substances extract of Garcinia mangostana, its medicinal usage belongs to first to be found, for the treatment hyperlipidemia, resist myocardial ischemia, treat coronary heart disease, new medicine source has been found in angina pectoris.
The dosage of active substance can be according to the mode of taking, patient's age and body weight and be in a bad way degree and other similar factor and change, and oral dose is: 70～120mg/ time, take for 1～2 time every day: inject 30～70mg/ time, once a day.
The specific embodiment
The present invention can further specify by following experimental example.Peel of Carcinia mangostana L. extract is hereinafter to be referred as SZGPT.
The preliminary test of experimental example one, SZGPT prevention and treatment hyperlipidemia
1, materials and methods
1.1 animal SD rat, 40, male and female half and half, body constitution amount 130g-150g is available from this school Experimental Animal Center.
1.2 medicine peel of Carcinia mangostana L. extract SZGPT: self-control; Radix Oenotherae erythrosepalae oil, Pharmaceutical Factory, Bethune Medical Univ. produces.Cholesterol powder (AR) provides (lot number F20030410) by China Medicine (Group) Shanghai Chemical Reagent Co..
1.3 the preparation high lipid food of high lipoprotein rabbit feedstuff and various pastille object height fat feedstuffs preparation: add cholesterol 0.4g, Adeps Sus domestica 2mL among the normal feedstuff 100g; The medicine that adds different content on the basis of high lipid food is mixed with the high lipid food that contains medicine and feeds for experiment.
2,40 of rats are got in the influence of normal rat fat level, male and female half and half, fasting feedwater 12h, claim the body constitution amount, be divided into 4 groups (each 10) at random: the normal control group (normal saline, 1ml/100g), positive controls (Radix Oenotherae erythrosepalae oil 1.2g/100g), the heavy dose of group of peel of Carcinia mangostana L. extract (0.84g/kg), middle dosage group (0.42g/kg) and small dose group (0.21g/kg).Said medicine is all irritated stomach (ig) administration, and every day 1 time, 15d claims body constitution amount 1 time weekly in the experimentation altogether, extracts rat eye on the 16th day, and eye socket is got blood 2-3ml, send the blood biochemical analysis, surveys TG and TC content in the serum.
3, peel of Carcinia mangostana L. extract extract blood fat reducing result of the test sees Table 1.
Table 1 peel of Carcinia mangostana L. extract blood fat reducing result of the test
| Grouping | TC(mmol/L) | TG(mmol/L) |
| The heavy dose of group of dosage group in the normal control group positive controls peel of Carcinia mangostana L. extract small dose group | 2.260±0.225 1.920±0.177 * 1.960±0.292 * 1.835±0.214 * 1.637±0.205 * | 1.513±0.351 1.241±0.235 1.073±0.365 * 1.040±0.173 * 1.035±0.154 * |
4, the conclusion experimental result shows that peel of Carcinia mangostana L. extract has tangible effect for reducing blood fat.
Experimental example two, SZGPT resist myocardial ischemia, treat coronary heart disease, anginal preliminary test
1. materials and methods
1.1 the animal health mongrel dogs, female, male dual-purpose, body weight 16.23 ± 1.87kg.
1.2 medicine and reagent peel of Carcinia mangostana L. extract (medicated powder), character: shallow rice-pudding toner end, purity: the peel of Carcinia mangostana L. extract general flavone content is no less than 2% in the sample, lot number: 031007, provide by regenerative medicine Science Institute of Jilin University; Positive control drug: Folium Ginkgo, specification: the 12mg/ sheet, contain total flavonoid glycoside 9.6mg, terpenoid lactone 2.4mg, lot number: 20031212, Guizhou Xinbang Pharmacy Stock Co., Ltd's product; Pentobarbital sodium, specification: analytical pure (25g/ bottle), lot number: 950427, Tong County, Beijing Fine Chemical Works product of cultivating people of ability; Heparin sodium injection, specification: 12500U:2ml, lot number: 0104108, Wanbang Biochemically Pharmaceutical Co Ltd, Xuzhou's product; The chlorination nitro blue tetrazolium, specification: analytical pure, lot number: F20020830, China Medicine's product; Glutamic oxaloacetic transaminase, GOT (AST) detection kit, specification: 10ml * 10, lot number: 020151, creatine kinase (CK) detection kit, specification: 10ml * 10, lot number: 090151, lactic acid dehydrogenase (LDH-L) detection kit, specification: 10ml * 10, lot number: 130081, Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd.'s product; Malonaldehyde (MDA) detection kit, specification: the 50T/ box, lot number: 20040322, superoxide dismutase (SOD) detection kit, specification: the 50T/ box, lot number: 20040323, bio-engineering research institute product is built up in Nanjing.
1.3 instrument CBI-8000 laser-Doppler blood flow instrument (U.S. BIOPAC company product) selects to be fit to bore blood flow probe according to laboratory animal coronary artery and aorta diameter; Powerlab/8s type eight derivatives are monitor and related accessories (Australian Ai De company product) according to one's analysis; SC-3 type artificial respirator (Shanghai Medical Equipment Factory's product); HL-2 type constant flow pump (Shanghai City Hu Xi instrument plant product); TU-1800S type ultraviolet-uisible spectrophotometer (Beijing Puxi General Instrument Co., Ltd's product); BI-2000 medical images analyser (Chengdu TME Technology Co., Ltd.'s product).
2. experimental technique
2.1 grouping and dosage are divided into matched group at random with experimental dog; Positive control drug Folium Ginkgo group (24mg/kg); Three dosage groups of peel of Carcinia mangostana L. extract 24mg/kg, 12mg/kg and 6mg/kg.Every group 6.Control drug and be subjected to the reagent thing to be mixed with the desired concn suspension with distilled water.
2.2 the operation method laboratory animal is anaesthetized with 3% pentobarbital sodium (30mg/kg) intravenous injection.Operation on neck, tracheal intubation connects artificial respirator, separates left carotid, and intubate writes down arteriotony through pressure transducer; Separate femoral vein, intubate is for liquid make-up or anaesthetic; Separate right common femoral artery and intubate to left ventricle, connect pressure transducer and measure left ventricular pressure and whole last pressure of left ventricular diastolic, measure the left ventricular pressure rate of change through differentiator again; Duodenal intubation is done in abdominal operation, for duodenal administration; Open breast, vertically cut off pericardium, do the fixing heart that holds up of pocket, isolate LCA and aortic root, place the laser-Doppler probe that is fit to bore, measure coronary artery blood flow and ABF (cardiac output) respectively.
3. observation index and detection method thereof
3.1 the foundation of myocardial infarction and ischemia model operation finishes, and stablize 30min, treat that every physical signs steadily after, the normalized curve that writes down every index earlier contrasts before as administration.Begin administration subsequently, positive control drug Folium Ginkgo and be subjected to the reagent YANGSHENGUO GUANXIN PIAN through duodenal administration, control animals gives the equal-volume distilled water through duodenum.45min after the administration, sets up the acute myocardial ischemia model by in the ligation left coronary artery left anterior descending branch following 1/3 section.During respectively at 2min, 5min after the ligation, 10min, 20min, 30min, 60min, 90min, 120min, 180min, 240min, 300min and 360min, 6h cardiac muscle three enzymes, SOD, MDA, myocardial infarction area percentage ratio after the surveying record coronary artery ligation.
3.2 cut heart when the experiment of myocardial infarction area measuring method finishes, clean with normal saline, remove blood stains, reject non-cardiac muscular tissues such as blood vessel fat, inhale the branch that anhydrates with absorbent paper, claim weight in wet base whole-heartedly.Cut off the above atrium of coronary sulcus, satisfactory chamber is heavy.Along coronary sulcus is parallel from the apex of the heart to the heart base portion ventricle is cut into the cardiac muscle section that thickness is 1cm, cleans with normal saline.The cardiac muscle section is positioned in 0.025% nitro blue tetrazolium (NBT) solution, and temperature is incubated 15min dyeing in 37 ℃ of water-baths, constantly stirs dyeing liquor in the dyeing course and makes it with cardiac muscle sufficient touch opportunity is arranged.The unnecessary dyestuff of water flushing immediately after the dyeing, normal myocardium is dyed blueness, and infarcted myocardium is not colored.Video device by BI-2000 medical images analytical system is taken in computer with each group cardiac muscle section with the picture form, determine the area and the monoblock myocardial area of calculating myocardium infarction again by the software of BI-2000 medical images analysis system processes area, available formula: myocardial infarction area=be unstained area and/the myocardium sheet gross area and * 100%.
4. result and discussion
Peel of Carcinia mangostana L. extract is to the influence of myocardial ischemia dog myocardial infarction area
6h after the coronary artery ligation, cut into slices by cardiac muscle, substantially specimen calculates the percentage ratio that myocardial infarction area accounts for the myocardium gross area through chlorination nitro blue tetrazolium (NBT) dyeing, can reflect the prophylactic treatment effect to heart infarction of the size of myocardial infarction area after the ligation and medicine intuitively.As can be seen from Table 2: 6h after the coronary artery ligation, the myocardial infarction area of matched group are 25.7 ± 4.0%; The myocardial infarction area of positive control phase medicine Folium Ginkgo 24mg/kg group was 18.1 ± 2.0% (comparing P＜0.01 with matched group); The myocardial infarction area that is tried new drug peel of Carcinia mangostana L. extract 24mg/kg, 12mg/kg and 6mg/kg dosage group is respectively 13.1 ± 2.9%, 19.1 ± 1.5% and 23.6 ± 1.5% (relatively being respectively P＜0.001, P＜0.01 and P＞0.05 with matched group).In addition, the myocardial infarction area that is tried new drug peel of Carcinia mangostana L. extract 24mg/kg dosage group also is significantly less than the positive control drug Folium Ginkgo (P＜0.01) of identical dosage.Above-mentioned experimental result shows, is tried the new drug peel of Carcinia mangostana L. extract under the myocardial ischemia condition, can coronary blood flow increasing, improve blood supply of cardiac muscle oxygen supply situation, treatment and prevention coronary heart disease, angina pectoris, minimizing myocardial infarction area.And this effect obviously is better than the positive control drug Folium Ginkgo of same dose.Detailed results sees Table 2.
Table 2. peel of Carcinia mangostana L. extract is to the influence (x ± s n=6) of myocardial ischemia dog cardiac muscle three enzymes, SOD, MDA and myocardial infarction area
| Group | Contrast | Folium Ginkgo (24mg/kg) | Peel of Carcinia mangostana L. extract (24mg/kg) | Peel of Carcinia mangostana L. extract (12mg/kg) | YANGSHENGUO GUANXIN PIAN (6mg/kg) | |
| Before the administration | LDH (U/L) CK (U/L) AST (U/L) SOD (U/ml) MDA (nmol/ml) | 362.6±44.7 1012.2±149.5 120.9±26.2 88.6±5.5 9.9±1.6 | 326.5±62.2 1038.9±232.0 120.0±25.2 91.4±7.9 10.2±2.1 | 346.6±30.0 1127.1±180.2 124.2±20.4 89.6±9.2 9.3±1.7 | 350.9±86.4 1010.3±185.3 114.2±32.6 96.4±8.7 8.7±2.1 | 335.1±58.0 996.1±317.5 121.2±31.5 97.1±7.9 9.1±2.1 |
| Behind the coronary ligation 6 hours | LDH (U/L) CK (U/L) AST (U/L) SOD (U/ml) MDA (nmol/ml) heart stalk area (%) | 712.6±116.4 2146.2±205.2 289.8±59.7 43.1±9.0 20.2±3.1 25.7±4.0 | 419.9±127.9 *** 1639.3±397.6 ** 218.0±59.4 * 52.1±7.0 * 14.5±3.1 ** 18.1±2.0 ** | 443.5±164.7 ** 1304.3±376.2 *** 197.0±44.6 ** 68.0±8.1 ***▲▲ 13.5±3.4 ** 13.1±2.9 ***▲▲ | 505.2±154.4 * 1524.4±500.2 ** 228.4±77.9 55.4±8.5 * 15.1±3.9 * 19.1±1.5 ** | 594.8±172.4 1741.3±471.6 * 244.7±77.8 47.5±9.5 17.2±4.6 23.6±1.5 |
Annotate: compare with matched group
*P＜0.05;
*P＜0.01;
* *P＜0.001.Compare with positive control drug Folium Ginkgo group
▲ ▲P＜0.01.
The embodiment 1 of extracting method:
A. peel of Carcinia mangostana L. is pulverized, under 80 ℃ of conditions,, be respectively 3h, 2h, 1h, filtration, merge extractive liquid, at every turn with 25 times of amount 30% ethanol extractions 3 times;
B. on the extracting solution that step a is obtained, reclaim ethanol to extractum, drying.
The embodiment 2 of extracting method:
A. peel of Carcinia mangostana L. is pulverized, under 30 ℃ of conditions,, be respectively 3h, 2h, 1h, filtration, merge extractive liquid, at every turn with 20 times of amount 95% ethanol extractions 3 times;
B. on the extracting solution that step a is obtained, reclaim ethanol to extractum, drying.
The embodiment 3 of extracting method:
A. peel of Carcinia mangostana L. is pulverized, under 50 ℃ of conditions,, be respectively 3h, 2h, 1h, filtration, merge extractive liquid, at every turn with 22 times of amount 60% ethanol extractions 3 times;
B. on the extracting solution that step a is obtained, reclaim ethanol to extractum, drying.
The embodiment 1 of preparation medicament:
Get peel of Carcinia mangostana L. extract 50g, add medical starch 250g, the two fully mixes, and makes 1000 capsules, and every heavy 0.3g contains mangosteen extract 50mg.
The embodiment 2 of preparation medicament:
Get peel of Carcinia mangostana L. extract 60g, add medical starch 240g, the two fully mixes, and makes 1000, and every heavy 0.3g contains peel of Carcinia mangostana L. extract 60mg.
Claims (3)
1, a kind of peel of Carcinia mangostana L. extract is characterized in that being prepared by following method:
A. peel of Carcinia mangostana L. is pulverized, under 30-80 ℃ of condition, doubly measured the 30%-95% ethanol extraction 3 times, be respectively 3h, 2h, 1h at every turn, filter merge extractive liquid, with 20-25;
B. the extracting solution that step a is obtained reclaims ethanol to extractum, drying.
2, a kind of method for preparing peel of Carcinia mangostana L. extract is characterized in that:
A. peel of Carcinia mangostana L. is pulverized, under 30-80 ℃ of condition, doubly measured the 30%-95% ethanol extraction 3 times, be respectively 3h, 2h, 1h at every turn, filter merge extractive liquid, with 20-25;
B. the extracting solution that step a is obtained reclaims ethanol to extractum, drying.
3, peel of Carcinia mangostana L. extract is used for lipidemia disease in preparation, resists myocardial ischemia, treats the application of coronary heart disease, anginal medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610016501 CN1833665A (en) | 2006-01-05 | 2006-01-05 | Mangosteen peel extracts, its extraction method and medicine use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610016501 CN1833665A (en) | 2006-01-05 | 2006-01-05 | Mangosteen peel extracts, its extraction method and medicine use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007103005986A Division CN101219183A (en) | 2006-01-05 | 2006-01-05 | Application of mangosteen rind extract in preparing medicament for treating myocardial ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1833665A true CN1833665A (en) | 2006-09-20 |
Family
ID=37001655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610016501 Pending CN1833665A (en) | 2006-01-05 | 2006-01-05 | Mangosteen peel extracts, its extraction method and medicine use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1833665A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816687A (en) * | 2010-03-26 | 2010-09-01 | 东北师范大学 | Method for extracting mangosteen pericarp anthocyanin and application thereof in preparing anti-inflammatory drugs |
| JP2011079752A (en) * | 2009-10-05 | 2011-04-21 | Kracie Home Products Ltd | Pancreatic lipase inhibitor, food and beverage composition containing the same and pharmaceutical composition |
| CN101396101B (en) * | 2008-09-17 | 2011-10-26 | 丁予章 | Production technique of mangosteen extract |
| CN102618071A (en) * | 2012-03-08 | 2012-08-01 | 桂林理工大学 | Method for extracting garcinia mangostana pericarp pigment by ultrasonic wave method |
| CN101525328B (en) * | 2008-03-06 | 2012-08-22 | 陕西嘉禾植物化工有限责任公司 | Method for extracting alpha-mangostin from mangosteen fruit peel |
| CN109362967A (en) * | 2018-11-05 | 2019-02-22 | 华中农业大学 | A plant extract feed additive for relieving pig oxidative stress and improving meat quality and its application |
-
2006
- 2006-01-05 CN CN 200610016501 patent/CN1833665A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525328B (en) * | 2008-03-06 | 2012-08-22 | 陕西嘉禾植物化工有限责任公司 | Method for extracting alpha-mangostin from mangosteen fruit peel |
| CN101396101B (en) * | 2008-09-17 | 2011-10-26 | 丁予章 | Production technique of mangosteen extract |
| JP2011079752A (en) * | 2009-10-05 | 2011-04-21 | Kracie Home Products Ltd | Pancreatic lipase inhibitor, food and beverage composition containing the same and pharmaceutical composition |
| CN101816687A (en) * | 2010-03-26 | 2010-09-01 | 东北师范大学 | Method for extracting mangosteen pericarp anthocyanin and application thereof in preparing anti-inflammatory drugs |
| CN101816687B (en) * | 2010-03-26 | 2011-09-28 | 东北师范大学 | Method for extracting mangosteen pericarp anthocyanin and application thereof in preparing anti-inflammatory drugs |
| CN102618071A (en) * | 2012-03-08 | 2012-08-01 | 桂林理工大学 | Method for extracting garcinia mangostana pericarp pigment by ultrasonic wave method |
| CN109362967A (en) * | 2018-11-05 | 2019-02-22 | 华中农业大学 | A plant extract feed additive for relieving pig oxidative stress and improving meat quality and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352552B (en) | A kind of food, health products or pharmaceutical composition | |
| CN1969822A (en) | Red sage root salvianolic acid A injection formulation for treating cardiovascular diseases and preparation process thereof | |
| CN107441078A (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN102228539A (en) | Rosa davurica total flavone extract, its extracting method and its medical use | |
| WO2010076922A1 (en) | Anticancer health food containing ginseng powder fermented with mushrooms | |
| CN115444893B (en) | Uric acid reducing active substance composition and application thereof | |
| CN1833665A (en) | Mangosteen peel extracts, its extraction method and medicine use | |
| CN100574768C (en) | A kind of anticancer pharmaceutical composition and its production and use | |
| US6476203B1 (en) | Safe pharmaceutical composition for treating and preventing infertility and increasing immune function | |
| CN1872094A (en) | Application of active material of sea cucumber as medication or health products | |
| CN106413730A (en) | Method for improving memory of a subject using a composition comprising cistanche and ginkgo extracts | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN101623437B (en) | Pulse-activating preparation for injection and preparation method thereof | |
| CN101703497A (en) | Application of Chlorogenic acid in preparing drug having protection and restoration functions on spleen hematopoietic stem cell injuries | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| CN101219183A (en) | Application of mangosteen rind extract in preparing medicament for treating myocardial ischemia | |
| CN101212963A (en) | The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells | |
| CN1839855A (en) | Ginsenoside F1 medicinal uses | |
| CN101695485B (en) | Use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia | |
| CN1559420A (en) | Medicne tablets with function of delaying senility, and prepn. method therefor | |
| CN107266406A (en) | α pyrone compounds and its pharmaceutical composition and its application in pharmacy | |
| CN106728962B (en) | Pharmaceutical composition for enhancing immunity and application thereof | |
| CN1872241A (en) | Compound medication of valerian for treating coronary heart disease, and preparation method | |
| CN1041599C (en) | Quick-acting cold oral liquid for child and preparing process thereof | |
| CN1778309A (en) | Use of arctiin and its aglycon in preparation of medicines for diabetes and nephrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20060920 |